25.18
Schlusskurs vom Vortag:
$24.98
Offen:
$24.93
24-Stunden-Volumen:
157.05K
Relative Volume:
0.45
Marktkapitalisierung:
$1.04B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-136.98M
KGV:
-6.2624
EPS:
-4.02
Netto-Cashflow:
$-126.63M
1W Leistung:
+21.57%
1M Leistung:
+39.79%
6M Leistung:
+6.89%
1J Leistung:
-10.01%
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Firmenname
Arrivent Biopharma Inc
Sektor
Branche
Telefon
240-780-6356
Adresse
18 CAMPUS BLVD., NEWTOWN SQUARE
Vergleichen Sie AVBP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
AVBP
Arrivent Biopharma Inc
|
25.18 | 1.03B | 0 | -136.98M | -126.63M | -4.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.92 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.15 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
418.13 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
893.47 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.88 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-25 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-03-20 | Eingeleitet | B. Riley Securities | Buy |
| 2025-03-10 | Eingeleitet | Guggenheim | Buy |
| 2024-07-22 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-02-20 | Eingeleitet | Citigroup | Buy |
| 2024-02-20 | Eingeleitet | Goldman | Buy |
| 2024-02-20 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Arrivent Biopharma Inc Aktie (AVBP) Neueste Nachrichten
ArriVent BioPharma (NASDAQ:AVBP) versus Sunshine Biopharma (NASDAQ:SBFM) Critical Review - Defense World
Buy Rating for ArriVent BioPharma, Inc. Driven by Promising Developments in EGFR Exon 20 NSCLC Treatment - TipRanks
Is ArriVent BioPharma Inc (AVBP) positioned for future growth? - Setenews
Buy Rating for ArriVent BioPharma Driven by Promising Firmonertinib Trial Results - TipRanks
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 6.4%Here's What Happened - MarketBeat
Understanding Momentum Shifts in (AVBP) - news.stocktradersdaily.com
How ArriVent BioPharma Inc. stock trades before earnings2025 Trading Volume Trends & Accurate Trade Setup Notifications - Newser
Will ArriVent BioPharma Inc. stock sustain high P E ratiosWeekly Market Outlook & Stepwise Trade Signal Implementation - Newser
A new trading data show ArriVent BioPharma Inc (AVBP) is showing positive returns. - Setenews
ArriVent BioPharma (NASDAQ:AVBP) Coverage Initiated at Truist Financial - MarketBeat
Truist Financial Initiates Coverage on ArriVent BioPharma (NASDAQ:AVBP) - Defense World
ArriVent Biopharma initiated with a Buy at Truist - TipRanks
ArriVent BioPharma stock initiated with Buy rating at Truist on lung cancer drug - Investing.com Canada
Truist Initiates ArriVent BioPharma at Buy With $43 Price Target - marketscreener.com
AXQ Capital LP Buys New Position in Intellia Therapeutics, Inc. $NTLA - Defense World
12,735 Shares in ArriVent BioPharma, Inc. $AVBP Acquired by AXQ Capital LP - MarketBeat
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Avoiding Lag: Real-Time Signals in (AVBP) Movement - news.stocktradersdaily.com
ArriVent Maps Ambitious 2026 Oncology Push as Firmonertinib Program Gains Steam - MSN
Is ArriVent BioPharma Inc. stock in correction or buying zoneCEO Change & Smart Money Movement Alerts - newser.com
Can ArriVent BioPharma Inc. stock outperform in 2025 bull marketEarnings Overview Summary & Momentum Based Trading Signals - newser.com
Best data tools to analyze ArriVent BioPharma Inc. stockJuly 2025 Big Picture & Smart Swing Trading Alerts - newser.com
How institutional ownership impacts ArriVent BioPharma Inc. stockWeekly Trade Recap & Stepwise Entry and Exit Trade Signals - newser.com
Will ArriVent BioPharma Inc. stock gain from lower inflationWeekly Profit Recap & Reliable Volume Spike Trade Alerts - newser.com
How ArriVent BioPharma Inc. stock reacts to Fed rate cutsGap Down & High Yield Equity Trading Tips - newser.com
Can momentum traders help lift ArriVent BioPharma Inc.Portfolio Value Summary & AI Forecasted Stock Moves - newser.com
Published on: 2025-11-19 02:02:03 - newser.com
Is ArriVent BioPharma Inc. stock a defensive play in 20252025 Volatility Report & Real-Time Chart Pattern Alerts - newser.com
Why Red River Bancshares, Inc. stock attracts strong analyst attention - newser.com
Evaluating ArriVent BioPharma Inc. with trendline analysisWeekly Risk Summary & Free Real-Time Market Sentiment Alerts - newser.com
Analyzing ArriVent BioPharma Inc. with risk reward ratio chartsJuly 2025 Decliners & Growth Oriented Trading Recommendations - newser.com
Published on: 2025-11-15 15:01:05 - newser.com
Why ArriVent BioPharma Inc. stock is favored by pension fundsLong Setup & Accurate Entry/Exit Alerts - newser.com
Momentum divergence signals in ArriVent BioPharma Inc. chartWeekly Stock Recap & Real-Time Volume Analysis - newser.com
What is the fair value of ArriVent BioPharma Inc. stock now2025 Earnings Impact & Fast Gain Stock Tips - Fundação Cultural do Pará
What is HC Wainwright’s Forecast for AVBP FY2025 Earnings? - Defense World
Here's Why We're Watching ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Situation - Sahm
Finanzdaten der Arrivent Biopharma Inc-Aktie (AVBP)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):